Post-earnings recap
Reported
Wed, Aug 7, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Madrigal Pharmaceuticals reported a loss of $1.28 per share, but there was no revenue reported or guidance provided. The stock reaction remained flat, indicating that investors may have anticipated the results. The focus now shifts to the company's ongoing clinical trials, as investors await more concrete updates in future quarters.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.28 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management maintained a neutral tone during the call, emphasizing ongoing projects without providing new insights or forecasts. The lack of specific guidance may leave investors seeking more clarity.
Management did not provide specific guidance for future quarters.
The company continues to focus on its ongoing clinical trials.